The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
CompletedPhase 2NCT01840345
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.
Study details
- Official title
- The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
- Conditions
- Interventions
- Drug: N-acetyl-l-cysteine
- Sponsor
- Virginia Commonwealth University
- Start date
- 2014-01
- Primary completion
- 2017-03-01
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * 18-65 years old * non-cancer neuropathic pain * stable dose of opioids for pain * using breakthrough pain meds * still with persistent pain per VAS Exclusion Criteria: * pregnant or nursing * serious medical or psychiatric illness (including uncontrolled hypertension) * active stomach ulcer, history or seizures or asthma * breakthrough pain meds other than opioids * using illicit drugs
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01840345